Antibody–Drug Conjugates (ADCs) have been through multiple cycles of technological
innovation since the concept was first practically demonstrated~ 40 years ago. Current …

This review highlights the potential of asialoglycoprotein receptor (ASGPR)-mediated
targeting in advancing liver-specific treatments and underscores the ongoing progress in the …

In this work, we have developed covalent and low molecular weight docetaxel delivery
systems based on conjugation with N-acetyl-d-galactosamine and studied their properties …

Herein, we describe the design, synthesis, and biological evaluation of novel betulin and N-
acetyl-d-galactosamine (GalNAc) glycoconjugates and suggest them as targeted agents …

Background: The pathogenesis of hepatic diseases involves several cells, which
complicates the delivery of pharmaceutical agents. Many severe liver diseases affecting the …

Drug targeting and nanomedicine are different strategies for improving the delivery of drugs
to their target. Several antibodies, immuno-drug conjugates and nanomedicines are already …

Liver cancer is the third most common cause of global cancer-related deaths. This study
focused on newly developed drug delivery systems with hepatocyte asialoglycoprotein …

Since the asialoglycoprotein receptor (also known as the “Ashwell–Morell receptor” or
ASGPR) was discovered as the first cellular mammalian lectin, numerous drug delivery …

New ligands for targeted delivery to the liver based on glycoconjugated natural triterpenoids
are proposed. Simple chemical transformations of starting lupane triterpenes led to betulin …

Abstract Purpose of Review Treatment of liver fibrosis benefits from hepatic stellate cell
(HSC)-specific delivery. Since the description of first carrier to HSC, many developments …